UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 13, 2025

SELECTIS HEALTH, INC.
(Exact Name of Registrant as Specified in its Charter)

Utah

0-15415

87-0340206

(State or other jurisdiction

of incorporation)

Commission File

Number

(I.R.S. Employer

Identification number)

8480 E. Orchard Road, Ste. 4900, Greenwood Village, CO 80111

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (720) 680-0808

(Former name or former address, if changed since last report)

☐	Written communications pursuant to Rule 425 under the Securities Act

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as deﬁned in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised ﬁnancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 1.02

TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT

Effective July 13, 2025, Selectis Health, Inc., a Utah corporation (the “Company”) received written notice from the Purchaser (“Purchaser”) under the Purchase and Sale Agreement (“PSA”) and Operations Transfer Agreement (“OTA”) for the sale of certain of its Georgia subsidiaries, as previously reported on its Current Report on Form 8-K dated February 7, 2025 and filed with the Securities and Exchange Commission on February 13, 2025, that the Purchaser was terminating the PSA and OTA without consummation.

The Company intends to pursue any and all rights and remedies in the matter.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Selectis Health, Inc. (Registrant)

Dated: July 16, 2025	/s/ Adam Desmond
	Adam Desmond, CEO

SELECTIS HEALTH, INC. 8-K